Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 316 results found. Search for [ COVID-19 vaccine Moderna ]

Results 1 to 21 of 316
BusinessToday.In
November 24, 2020
Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first


BusinessToday.In
November 23, 2020
Centre is worried about the caseload surge in urban centres, which has resulted in the enforcement of measures such as curfews by state governments.


BusinessToday.In
November 23, 2020
Indian Council of Medical Research is working closely with SII for Covishield vaccine trials across 15 centres in India, and would also be funding the clinical trials in the country.


BusinessToday.In
November 23, 2020
Earlier on Monday, the Oxford-AstraZeneca team announced that one of the dosing regimens of the vaccine might be 90% effective in preventing COVID-19 infection


BusinessToday.In
November 23, 2020
Vaccine can be easily manufactured, transported and stored at domestic fridge temperature (2-8 degrees C). This means it can be easily distributed using existing medical facilities such as doctor's surgeries and local pharmacies, allowing for the vaccine to be deployed very rapidly, said Oxford University


BusinessToday.In
November 23, 2020
The panel-led by Dravida Munnetra Kazhagam (DMK) lawmaker Kanimozhi Karunanidhi will hear officials of pharmaceutical departments on the status of the COVID-19 vaccine


BusinessToday.In
November 23, 2020
The Prime Minister is expected to hold two back-to-back meetings, one with those states with high caseloads and another related to vaccine distribution strategy.


BusinessToday.In
November 22, 2020
USFDA Commissioner Stephen Hahn said that USFDA has been preparing for review of EUAs for COVID-19 vaccines for the past several months and requests will be processed \"as expeditiously as possible\"


BusinessToday.In
November 22, 2020
Bharat Biotech has started the phase- 3 trial of its potential COVID-19 vaccine, involving 26,000 volunteers this month across 25 centres in the country, including Hyderabad, Goa, Nagpur, Bhubaneswar, and Aligarh


Reuters
November 22, 2020
The twin crises of the pandemic and an uneven, uncertain global recovery dominated the first day of a two-day summit under the chairmanship of Saudi Arabia, which hands off the rotating presidency of the G20 to Italy next month


Reuters
November 22, 2020
On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose


BusinessToday.In
November 21, 2020
Bharat Biotech, the developer of India's indigenous vaccine Covaxin, has said that it is planning to enrol about 2,000 participants each in metros for Phase-3 trials of its COVID-19 vaccine that began earlier this week


BusinessToday.In
November 21, 2020
Pfizer's CEO Albert Bourla confirmed the company's application and said in a video statement,  'It is with great pride and joy - and even a little relief - that I can say that our request for emergency use authorization for our COVID-19 vaccine is now in the FDA's hands.'


BusinessToday.In
November 21, 2020
Pfizer that its EUA submission is supported by solicited safety data from a randomised subset of approximately 8,000 participants aged 18 years or above and unsolicited safety data from approximately 38,000 trial participants


Associated Press
November 20, 2020
The European commission has sealed deals with several pharmaceutical companies including BioNTech and Pfizer to buy millions of doses of vaccines on behalf of all EU Member States


BusinessToday.In
November 20, 2020
Adar Poonawalla said if things go according to the plan, the coronavirus vaccine will be available for vulnerable populations by January or February. And, in March or April, the vaccine will enter the market for the general public


Rajeev Dubey
November 20, 2020
Emboldened, firms indulge in a game of one-upmanship based on alarmingly low number of trials. Sputnik had been tried on only 20 patients before Gamaleya made the claim; Pfizer 120 and Moderna 95


BusinessToday.In
New Delhi, November 19, 2020
A fast and cheap coronavirus testing kit that can provide results in 40 minutes was launched in Delhi on Thursday. The indigenously developed testing kit for coronavirus based on the gene-editing technology CRISPR called Feluda was launched by Tata group in collaboration with the Apollo group of hospitals. The test is likely to be cheaper than the current gold standard RT-PCR and equally accurate, helping in scaling up COVID-19 testing. Watch the video for more.Also Read: Pfizer share rises nearly 7% after firm says COVID-19 vaccine 95% effective


BusinessToday.In
November 19, 2020
Pharmaceutical industry giant Pfizer and its German partner BioNTech had stated on November 18 that their vaccine candidate was 95 per cent effective in preventing COVID-19 infections during late-stage trials


Rupa Burman Roy
November 19, 2020
Equities also stepped back after soft US retail sales data. Economic restrictions after the closure of the public school system in New York also kept sentiments tepid today across all markets, leading to profit booking.


PAGES 1 OF 16  12345